Quick answer
KPV is a tiny three-amino-acid peptide (Lys-Pro-Val). It is the end piece of alpha-MSH. Researchers study it mainly in inflammation models. CoreVials KPV is for laboratory research only, not for human or animal use.
Alpha-MSH is a larger hormone fragment involved in pigment and immune signaling. KPV keeps a slice of the anti-inflammatory research interest without the pigment story that full alpha-MSH carries in many summaries.
Protocol math helpers: the KPV 10mg protocol page and the volume calculator.
What is KPV?
KPV stands for lysine-proline-valine. It is short, which makes it a handy tool when labs want a compact melanocortin-related fragment.
Early work identified the C-terminal tripeptide of alpha-MSH as enough to retain anti-inflammatory activity in some animal contact-inflammation setups.
What have studies looked at?
Most published KPV work is preclinical. Common themes:
- Lowering certain pro-inflammatory cytokine signals in cell systems
- NF-kappaB and MAPK pathway readouts after inflammatory challenge
- Mouse colitis models (DSS / TNBS) where oral KPV changed disease-activity style scores
A frequently cited mechanistic paper reported PepT1-mediated uptake of KPV into intestinal epithelial and immune cells, with reduced inflammatory signaling in those systems.
What KPV is not
- Not a proven human therapy for IBD or skin disease
- Not the same as full alpha-MSH
- Not a substitute for controlled clinical evidence
Research boundary: Frame KPV as an investigational research compound. Do not treat lab notes as medical advice. Confirm documentation via COA lookup when available.
Bottom line
- KPV = Lys-Pro-Val, C-terminal alpha-MSH fragment
- Main research lane: inflammation signaling in cells and animals
- Human efficacy packages are not established like approved medicines
- Laboratory research use only
References
- Dalmasso, G., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. DOI
- Wang, W., et al. (2019). Melanocortin regulation of inflammation. Frontiers in Endocrinology. DOI
- Hiltz, M.E., & Lipton, J.M. (1989). Antiinflammatory activity of a COOH-terminal fragment of the alpha-MSH sequence. FASEB Journal.
